samidorphan; 3-carboxamido-4-hydroxynaltrexone

Indications

• investigstional use in combination with buprenorphine for treatment of depression (not FDA-approved Jan 2021)
• use in combination with olanzapine for treatment of schizophrenia (FDA-approved Jan 2021) Adverse events:
• consistent with antagonism of kappa opioid receptors
  • somnolence
  • sedation
  • dizziness
  • hallucinations

Mechanism of action

• mu opioid receptor antagonist

More general terms

• opioid receptor antagonist or narcotic antagonist

Component of

• olanzapine/samidorphan

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11667832
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53362094